IGC Pharma, Inc.
$0.32
▼
-2.32%
2026-04-21 07:28:00
igcpharma.com
ASE: IGC
Explore IGC Pharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$31.52 M
Current Price
$0.32
52W High / Low
$0.5 / $0.24
Stock P/E
—
Book Value
$0.09
Dividend Yield
—
ROCE
-114.73%
ROE
-83.34%
Face Value
—
EPS
$-0.06
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
70
Beta
0.31
Debt / Equity
1.8
Current Ratio
1.32
Quick Ratio
0.68
Forward P/E
-3.35
Price / Sales
26.97
Enterprise Value
$27.05 M
EV / EBITDA
-3.6
EV / Revenue
24.46
Rating
Strong Buy
Target Price
$4.12
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Tiziana Life Sciences Ltd | $1.21 | — | $143.81 M | — | -401.27% | -2.32% | $2.6 / $0.87 | $0.08 |
| 2. | Cyclerion Therapeutics, Inc. | $3 | — | $13.08 M | — | -40.99% | -39.34% | $8.48 / $1.03 | $2.38 |
| 3. | Coherus Oncology, Inc. | $1.99 | 1.76 | $295.28 M | — | -155.52% | -473.47% | $2.62 / $0.71 | $0.5 |
| 4. | Ginkgo Bioworks Holdings, Inc. | $7.98 | — | $492.71 M | — | -29.68% | -51.08% | $17.58 / $5.37 | $8.74 |
| 5. | YD Bio Ltd | $5.31 | — | $382.42 M | — | -22.15% | -42.69% | $31 / $5.12 | $4.57 |
| 6. | Syndax Pharmaceuticals, Inc. | $23.78 | — | $2.1 B | — | -66.67% | -1.62% | $25.59 / $8.58 | $0.74 |
| 7. | Cingulate Inc. | $6.03 | — | $66.77 M | — | -418.81% | -4.51% | $11.89 / $3.2 | $0.35 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.35 M | 0.19 M | 0.33 M | 0.33 M | 0.26 M | — |
| Operating Profit | -2.94 M | -2.9 M | -1.91 M | -1.41 M | -1.88 M | — |
| Net Profit | -0.73 M | -1.82 M | -1.6 M | -1.2 M | -1.83 M | — |
| EPS in Rs | -0.01 | -0.02 | -0.02 | -0.01 | -0.02 | -0.02 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.27 M | 1.34 M | 0.91 M | 0.4 M |
| Operating Profit | -7.45 M | -9.8 M | -11.57 M | -15.43 M |
| Net Profit | -7.12 M | -13 M | -11.51 M | -15.02 M |
| EPS in Rs | -0.07 | -0.13 | -0.12 | -0.15 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 8.75 M | 9.9 M | 17.18 M | 26.83 M |
| Total Liabilities | 2.42 M | 2.58 M | 2.27 M | 2.94 M |
| Equity | 6.33 M | 7.32 M | 14.91 M | 23.89 M |
| Current Assets | 2.9 M | 3.71 M | 6.47 M | 15.11 M |
| Current Liabilities | 2.26 M | 2.34 M | 1.9 M | 2.44 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -4.07 M | -5.2 M | -7.05 M | -7.46 M |
| Investing CF | -0.3 M | -0.32 M | -0.23 M | -0.74 M |
| Financing CF | 3.65 M | 3.52 M | 0.1 M | 4.14 M |
| Free CF | -4.38 M | -5.71 M | -7.67 M | -8.23 M |
| Capex | -0.32 M | -0.52 M | -0.62 M | -0.77 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -5.5% | 47.64% | 129.47% | — |
| Earnings Growth % | 45.22% | -12.98% | 23.38% | — |
| Profit Margin % | -560.27% | -966.54% | -1263.01% | -3782.37% |
| Operating Margin % | -585.84% | -728.48% | -1270.14% | -3886.15% |
| Gross Margin % | 48.7% | 54.5% | 48.52% | 48.87% |
| EBITDA Margin % | -549.33% | -681.12% | -1198.02% | -3722.17% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.